A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer
- PMID: 31200844
- DOI: 10.1016/j.euo.2019.02.001
A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer
Abstract
Context: There is uncertainty regarding the oncologic effectiveness and the survival advantage of local treatment (LT) in men with clinically lymph node-positive (cN+) prostate cancer (PCa).
Objective: To systematically review the current literature comparing oncologic outcomes associated with the use of any form of LT for PCa patients with cN+ disease.
Evidence acquisition: A computerized bibliographic search of the Medline, Embase, and Cochrane databases was performed for all studies reporting comparative oncologic outcomes of LT±androgen deprivation therapy (ADT) versus ADT alone. LT included both radical prostatectomy (RP) and radiotherapy (RT). Using the methodology recommended by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, we identified five nonrandomized comparative retrospective studies published between 1999 and 2018, which were eligible for inclusion in this systematic review. A narrative review and risk-of-bias assessment were performed to determine the impact of LT on recurrence-free survival, cancer-specific survival (CSS), and overall survival (OS).
Evidence synthesis: Four studies compared the use of RT±ADT versus ADT alone, whereas one study compared any form of LT±ADT versus ADT alone. Different statistical strategies were used in the included studies to account for baseline measured and unmeasured confounders. Overall, the use of RT and, generally speaking, any form of LT was associated with an OS as well as a CSS benefit over ADT alone, without any clear superiority shown either by RP±ADT or by RT±ADT.
Conclusions: Our systematic review suggests an advantage in terms of both OS and CSS for men with cN+ PCa receiving LT. However, these results should be interpreted with caution due to the low level of evidence of available reports.
Patient summary: We reviewed the studies that assessed the role of local treatment in men with prostate cancer and with clinical evidence of lymph node involvement at diagnosis. We found that local treatment was constantly associated with recurrence-free, cancer-specific, and overall survival benefits throughout the included studies.
Keywords: Local treatment; Lymph nodes; Prostate cancer.
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Management of Prostate Cancer Patients with Clinically Positive Lymph Nodes.Eur Urol Oncol. 2019 May;2(3):302-303. doi: 10.1016/j.euo.2019.04.010. Epub 2019 May 15. Eur Urol Oncol. 2019. PMID: 31103720 No abstract available.
Similar articles
-
Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy: A meta-analysis.Medicine (Baltimore). 2020 Mar;99(10):e19153. doi: 10.1097/MD.0000000000019153. Medicine (Baltimore). 2020. PMID: 32150055 Free PMC article.
-
Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.Eur Urol Oncol. 2020 Oct;3(5):565-581. doi: 10.1016/j.euo.2020.08.005. Epub 2020 Sep 12. Eur Urol Oncol. 2020. PMID: 32933887
-
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.Eur Urol. 2020 May;77(5):614-627. doi: 10.1016/j.eururo.2020.01.033. Epub 2020 Mar 4. Eur Urol. 2020. PMID: 32146018
-
Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis.Eur Urol. 2018 Mar;73(3):452-461. doi: 10.1016/j.eururo.2017.08.011. Epub 2017 Sep 8. Eur Urol. 2018. PMID: 28890245
-
Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.Eur Urol. 2018 Jun;73(6):890-896. doi: 10.1016/j.eururo.2017.09.027. Epub 2017 Oct 16. Eur Urol. 2018. PMID: 29042125 Free PMC article.
Cited by
-
Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting.Radiol Med. 2022 Feb;127(2):206-213. doi: 10.1007/s11547-021-01435-8. Epub 2021 Nov 30. Radiol Med. 2022. PMID: 34850352
-
E-Cadherin, Integrin Alpha2 (Cd49b), and Transferrin Receptor-1 (Tfr1) Are Promising Immunohistochemical Markers of Selected Adverse Pathological Features in Patients Treated with Radical Prostatectomy.J Clin Med. 2021 Nov 27;10(23):5587. doi: 10.3390/jcm10235587. J Clin Med. 2021. PMID: 34884287 Free PMC article.
-
Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study.Cancers (Basel). 2021 Jul 31;13(15):3868. doi: 10.3390/cancers13153868. Cancers (Basel). 2021. PMID: 34359768 Free PMC article.
-
Topography of Prostate Cancer Recurrence: A Single-centre Analysis of Salvage Radical Prostatectomy Specimens and Implications for Focal Salvage Treatments.Eur Urol Open Sci. 2022 Dec 15;47:110-118. doi: 10.1016/j.euros.2022.11.017. eCollection 2023 Jan. Eur Urol Open Sci. 2022. PMID: 36601045 Free PMC article.
-
Development of machine learning prognostic models for overall survival of prostate cancer patients with lymph node-positive.Sci Rep. 2023 Oct 27;13(1):18424. doi: 10.1038/s41598-023-45804-x. Sci Rep. 2023. PMID: 37891423 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical